Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-03-12EMA Authorised: Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto) (lenalidomide hydrochloride monohydrate) — Krka, d.d., Novo mesto
EMA authorised Lenalidomide Krka (lenalidomide hydrochloride monohydrate) for several hematologic malignancies, including multiple myeloma, …
-
FDA approval · 2026-03-12FDA Approved: POMALIDOMIDE — Supplemental Application (Teva Pharmaceuticals, Inc.)
The FDA approved Teva's supplemental application for pomalidomide, authorizing the generic pomalidomide to be marketed. This represents a su…
-
FDA approval · 2026-03-05FDA Approved: TALVEY — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for TALVEY (talquetamab) from Janssen Biotech, Inc.
-
EMA approval · 2026-02-24EMA Authorised: Lenalidomide Accord (lenalidomide) — Accord Healthcare S.L.U.
EMA has authorised Lenalidomide Accord for the treatment of multiple myeloma. The product is marketed by Accord Healthcare S.L.U.
-
FDA approval · 2026-02-12FDA Approved: DARZALEX FASPRO — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) from Janssen Biotech, Inc., to update the p…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2026-01-28EMA Authorised: Pomalidomide Teva (Pomalidomide) — Teva GmbH
EMA has authorised Teva GmbH's pomalidomide product for the treatment of multiple myeloma; decision date 28 January 2026.
-
EMA approval · 2026-01-20EMA Authorised: Imnovid (previously Pomalidomide Celgene) (Pomalidomide) — Bristol-Myers Squibb Pharma EEIG
The EMA authorised Imnovid (pomalidomide) for use in multiple myeloma, with Bristol-Myers Squibb Pharma EEIG as the marketing authorization …
-
EMA approval · 2026-01-16EMA Authorised: Elrexfio (elranatamab) — Pfizer Europe MA EEIG
The EMA authorised Elrexfio (elranatamab) for multiple myeloma under conditional approval by Pfizer Europe MA EEIG.
-
FDA approval · 2026-01-06FDA Approved: BORTEZOMIB — Original Application (Gland Pharma Limited)
FDA approved the original application for Bortezomib from Gland Pharma Limited as a generic injectable, covering indications established for…
-
FDA approval · 2025-12-29FDA Approved: POMALIDOMIDE — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Camber Pharmaceuticals’ pomalidomide, providing a generic version of pomalidomide under the …
-
EMA approval · 2025-12-09EMA Authorised: Abecma (idecabtagene vicleucel) — Bristol-Myers Squibb Pharma EEIG
The European Medicines Agency authorised Abecma (idecabtagene vicleucel) for treatment of multiple myeloma in adults. It is designated as an…
-
CLINICAL_TRIALS approval · 2025-12-09Clinical Trial Update: Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma
The update reports that Janssen's talquetamab for relapsed or refractory multiple myeloma has been approved for marketing under a pre-approv…
-
EMA approval · 2025-11-28EMA Authorised: Talvey (talquetamab) — Janssen-Cilag International N.V.
The European Medicines Agency authorised Talvey (talquetamab) for the treatment of multiple myeloma, with conditional approval and orphan me…
-
EMA approval · 2025-11-28EMA Authorised: Kyprolis (carfilzomib) — Amgen Europe B.V.
The European Medicines Agency authorised Kyprolis (carfilzomib) for the treatment of multiple myeloma. The decision was made on 14 December …
-
CLINICAL_TRIALS approval · 2025-11-10Clinical Trial Update: Compassionate Use (CU) of REGN5458 for Patients With Relapsed or Refractory Multiple Myeloma (MM)
Regeneron reports compassionate-use access for REGN5458 in relapsed or refractory multiple myeloma, and the trial page notes that REGN5458 h…
-
EMA approval · 2025-11-06EMA Authorised: Lenalidomide Mylan (lenalidomide) — Mylan Ireland Limited
The European Medicines Agency authorised Lenalidomide Mylan (lenalidomide) by Mylan Ireland Limited for the treatment of multiple myeloma.
-
FDA approval · 2025-10-23FDA Approved: BLENREP — Original Application (GlaxoSmithKline LLC)
FDA approved BLENREP (belantamab mafodotin) via its original application. It is indicated for adults with relapsed or refractory multiple my…
-
EMA approval · 2025-10-14EMA Authorised: Bortezomib Sun (bortezomib) — SUN Pharmaceutical Industries (Europe) B.V.
The European Medicines Agency authorised Bortezomib Sun by SUN Pharmaceutical Industries (Europe) B.V. for use in multiple myeloma.
-
EMA approval · 2025-10-08EMA Authorised: Tecvayli (teclistamab) — Janssen-Cilag International N.V.
The European Medicines Agency authorised Tecvayli (teclistamab) for the treatment of multiple myeloma. The approval is conditional.
-
FDA approval · 2025-10-02FDA Approved: TECVAYLI — Supplemental Application (Janssen Biotech, Inc.)
FDA approved a supplemental application for TECVAYLI (teclistamab-cqyv) by Janssen Biotech, Inc., resulting in a label update for its use.
-
FDA approval · 2025-10-02FDA Approved: TALVEY — Supplemental Application (Janssen Biotech, Inc.)
The FDA approved Janssen's supplemental application for TALVEY (talquetamab), authorizing an update to the product labeling related to its i…
-
EMA approval · 2025-10-01EMA Authorised: Farydak (panobinostat lactate anhydrous) — pharmaand GmbH
The EMA authorised Farydak (panobinostat lactate anhydrous) for the treatment of multiple myeloma. The marketing authorization holder is pha…
-
EMA approval · 2025-09-29EMA Authorised: Empliciti (Elotuzumab) — Bristol-Myers Squibb Pharma EEIG
EU authorities have authorised Empliciti (elotuzumab) for multiple myeloma.
-
EMA approval · 2025-09-25EMA Authorised: Zoledronic acid Teva (zoledronic acid) — Teva B.V.
The EMA authorised Teva B.V.'s Zoledronic acid product for bone-related conditions and cancer-related bone disease. The active substance is …
-
EMA approval · 2025-09-15EMA Authorised: Thalidomide Lipomed (thalidomide) — Lipomed GmbH
The European Medicines Agency authorised Thalidomide Lipomed (thalidomide) by Lipomed GmbH for use in multiple myeloma.